Average Sales Price Unveiled; IG Will Monitor Part B Market In 2005
Executive Summary
The HHS Inspector General will monitor prices for drugs covered under Medicare Part B to determine whether the "average sales price" accurately reflects market prices once payment rates for 2005 are finalized this fall
You may also be interested in...
Oncologists’ Costs For Three Drugs Would Exceed Reimbursement – GAO
Acquisition costs for three chemotherapy drugs would exceed projected Medicare reimbursement rates in 2005, a Government Accountability Office analysis using preliminary average sales price data finds
Oncologists’ Costs For Three Drugs Would Exceed Reimbursement – GAO
Acquisition costs for three chemotherapy drugs would exceed projected Medicare reimbursement rates in 2005, a Government Accountability Office analysis using preliminary average sales price data finds
CMS Updates 2005 Part B Payment Rates; Gemzar ASP Increases By 7.3%
Lilly has reversed a 7% price cut for the oncologic Gemzar ahead of the 2005 transition to average sales price-based reimbursement under Medicare Part B